Inotiv

Inotiv, Inc.
Company typePublic company
NasdaqNOTV
IndustryPharmaceutical industry
Founded1974; 50 years ago (1974) as Bioanalytical Systems
FounderPeter Kissinger
HeadquartersLafayette, Indiana, United States
Key people
ServicesContract research organization
Revenue
  • Increase US$572 million (2023)
  • Increase -US$81 million (2023)
  • Increase -US$105 million (2023)
Total assets
  • Decrease US$856 million (2023)
Total equity
  • Decrease US$269 million (2023)
Number of employees
1,200+ (2020)
Websitewww.inotiv.com
Footnotes / references
[1]

Inotiv, Inc. is a contract research organization organized in Indiana and headquartered in Lafayette, Indiana. The company operates two core business units: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The CRS business unit offers drug development and environmental sciences services, including safety assessment, analytical, metabolism, CMC and regulatory consultancy for small molecule drug candidates, biotherapeutics, and biomedical devices. The RMS business unit provides research models (live animals), lab animal diets and bedding and support services.[1]

The company has been criticized for its animal testing practices, most specifically animal testing on non-human primates as well as on beagles. It has also been criticized for its laboratory animal sources. In 2022, the United States Department of Agriculture found multiple violations of the Animal Welfare Act of 1966 at the company's dog-breeding facility in Cumberland, Virginia, to which the company plead guilty, resulting in $35 million in fines. The company is accredited by AAALAC International.[2]

  1. ^ a b "Inotiv, Inc. Form 10-K Annual Report for the Fiscal Year Ended September 30, 2023". U.S. Securities and Exchange Commission. December 12, 2023.
  2. ^ "Directory of Accredited Organizations Search Result". AAALAC International.